Advertisement
Research Article| Volume 132, ISSUE 2, P360-365, February 2014

Download started.

Ok

The value of re-exploration in patients with inadvertently morcellated uterine sarcoma

  • Author Footnotes
    1 Present address: Johns Hopkins School of Public Health, Baltimore, MD, United States.
    Titilope Oduyebo
    Footnotes
    1 Present address: Johns Hopkins School of Public Health, Baltimore, MD, United States.
    Affiliations
    Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, United States

    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Alejandro J. Rauh-Hain
    Affiliations
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Emily E. Meserve
    Affiliations
    Division of Women's & Perinatal Pathology, Department of Pathology & Laboratory Medicine, Brigham & Women's Hospital, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Michael A. Seidman
    Affiliations
    Division of Women's & Perinatal Pathology, Department of Pathology & Laboratory Medicine, Brigham & Women's Hospital, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Emily Hinchcliff
    Affiliations
    Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, United States

    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Suzanne George
    Affiliations
    Harvard School of Medicine, Boston, MA, United States

    Dana Farber Cancer Institute, Boston, MA, United States
    Search for articles by this author
  • Bradley Quade
    Affiliations
    Division of Women's & Perinatal Pathology, Department of Pathology & Laboratory Medicine, Brigham & Women's Hospital, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Marisa R. Nucci
    Affiliations
    Division of Women's & Perinatal Pathology, Department of Pathology & Laboratory Medicine, Brigham & Women's Hospital, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Marcela G. Del Carmen
    Affiliations
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Michael G. Muto
    Correspondence
    Corresponding author at: Division of Gynecologic Oncology, Obstetrics and Gynecology, Brigham and Women's Hospital, 75 Francis Street, ASBI 3rd Floor, Boston, MA 02115, United States. Fax: +1 617 738 5124.
    Affiliations
    Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, United States

    Harvard School of Medicine, Boston, MA, United States
    Search for articles by this author
  • Author Footnotes
    1 Present address: Johns Hopkins School of Public Health, Baltimore, MD, United States.
Published:December 30, 2013DOI:https://doi.org/10.1016/j.ygyno.2013.11.024

      Highlights

      • Morcellation appears to be changing the natural history of uterine leiomyosarcoma (ULMS) and smooth muscle tumor of uncertain-potential (STUMP).
      • Patients with morcellated sarcomas appear to be at an increased risk for disseminated intraperitoneal recurrence.
      • Surgical re-exploration may yield useful information regarding staging in patients with incidental ULMS/STUMP after morcellation for presumed benign disease.

      Abstract

      Objective

      To describe the role of immediate re-exploration in patients with inadvertently morcellated uterine leiomyosarcoma (ULMS) and smooth muscle tumors of uncertain malignant potential (STUMP).

      Methods

      All patients with ULMS/STUMP who were managed or referred to the participating institutions from January 2005 to January 2012 following minimally invasive gynecology surgery with morcellation were detected through the pathology database. The diagnosis was confirmed by gynecologic-pathologists following post-surgery pathology review.

      Results

      Twenty-one patients with the diagnosis of ULMS (N = 15) and STUMP (N = 6) after morcellation were identified. The median age of occurrence was 46 years (range, 25–58 years). Median follow-up duration was 27 months (range, 1.8–93.1 months). None of the 21 patients had documented evidence of extra-uterine disease at the time of original surgery. Ultimately 12 patients were immediately re-explored to complete staging. The median time to the staging surgery was 33 days (range 15–118 days). Two (28.5%) out of seven patients with presumed stage I ULMS and one (25%) out of four patients with presumed stage I STUMP had significant findings of disseminated intraperitoneal disease detected at immediate surgical re-exploration. One of the 8 patients with confined early ULMS and STUMP at the second surgery had intraperitoneal recurrence, while the remaining 7 patients have had no recurrence and remain disease free.

      Conclusion

      Surgical re-exploration is likely to show findings of disseminated peritoneal sarcomatosis in a significant number of patients diagnosed with ULMS after a morcellation procedure. Findings from re-exploration can contribute to the knowledge of natural history of morcellated ULMS/STUMP and allow for accurate prognostication.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baird D.D.
        • Dunson D.B.
        • Hill M.C.
        • Cousins D.
        • Schectman J.M.
        High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.
        Am J Obstet Gynecol. 2003; 188: 100-107
        • Wallach E.E.
        • Vlahos N.F.
        Uterine myomas: an overview of development, clinical features, and management.
        Obstet Gynecol. 2004; 104: 393-406
        • Schwartz L.B.
        • Diamond M.P.
        • Schwartz P.E.
        Leiomyosarcomas: clinical presentation.
        Am J Obstet Gynecol. 1993; 168: 180-183
        • Leibsohn S.
        • d'Ablaing G.
        • Mishell Jr., D.R.
        • Schlaerth J.B.
        Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.
        Am J Obstet Gynecol. 1990; 162: 968-974
        • Park J.Y.
        • Park S.K.
        • Kim D.Y.
        • et al.
        The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
        Gynecol Oncol. 2011; 122: 255-259
        • Einstein M.H.
        • Barakat R.R.
        • Chi D.S.
        • et al.
        Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.
        Int J Gynecol Cancer. 2008; 18: 1065-1070
        • Prat J.
        FIGO staging for uterine sarcomas.
        Int J Gynaecol Obstet. 2009; 104: 177-178
        • Chapron C.
        • Fauconnier A.
        • Goffinet F.
        • Breart G.
        • Dubuisson J.B.
        Laparoscopic surgery is not inherently dangerous for patients presenting with benign gynaecologic pathology. Results of a meta-analysis.
        Hum Reprod. 2002; 17: 1334-1342
        • Bekkers R.L.
        • Willemsen W.N.
        • Schijf C.P.
        • Massuger L.F.
        • Bulten J.
        • Merkus J.M.
        Leiomyomatosis peritonealis disseminata: does malignant transformation occur? A literature review.
        Gynecol Oncol. 1999; 75: 158-163
        • Cucinella G.
        • Granese R.
        • Calagna G.
        • Somigliana E.
        • Perino A.
        Parasitic myomas after laparoscopic surgery: an emerging complication in the use of morcellator? Description of four cases.
        Fertil Steril. 2011; 96: e90-e96
        • Steiner R.A.
        • Wight E.
        • Tadir Y.
        • Haller U.
        Electrical cutting device for laparoscopic removal of tissue from the abdominal cavity.
        Obstet Gynecol. 1993; 81: 471-474
        • Larrain D.
        • Rabischong B.
        • Khoo C.K.
        • Botchorishvili R.
        • Canis M.
        • Mage G.
        “Iatrogenic” parasitic myomas: unusual late complication of laparoscopic morcellation procedures.
        J Minim Invasive Gynecol. 2010; 17: 719-724
        • Perri T.
        • Korach J.
        • Sadetzki S.
        • Oberman B.
        • Fridman E.
        • Ben-Baruch G.
        Uterine leiomyosarcoma: does the primary surgical procedure matter?.
        Int J Gynecol Cancer. 2009; 19: 257-260
        • Leitao M.M.
        • Sonoda Y.
        • Brennan M.F.
        • Barakat R.R.
        • Chi D.S.
        Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.
        Gynecol Oncol. 2003; 91: 209-212
        • Seidman M.A.
        • Oduyebo T.
        • Muto M.G.
        • Crum C.P.
        • Nucci M.R.
        • Quade B.J.
        Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms.
        PLoS One. 2012; 7: e50058
        • Ip P.P.
        • Tse K.Y.
        • Tam K.F.
        Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
        Adv Anat Pathol. 2010; 2: 91-112
        • Hensley M.L.
        • Wathen J.K.
        • Maki R.G.
        • Araujo D.M.
        • Sutton G.
        • Priebat D.A.
        • George S.
        • Soslow R.A.
        • Baker L.H.
        Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
        Cancer. 2013; 8: 1555-1561
        • Brooks S.E.
        • Zhan M.
        • Cote T.
        • Baquet C.R.
        Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999.
        Gynecol Oncol. 2004; 93: 204-208
        • Hensley M.L.
        • Ishill N.
        • Soslow R.
        • et al.
        Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study.
        Gynecol Oncol. 2009; 112: 563-567
        • Reed N.S.
        • Mangioni C.
        • Malmstrom H.
        • et al.
        Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
        Eur J Cancer. 2008; 44: 808-818